Global PD-L1 and PIK3CA Testing Market Size, Share, Trends and Forecast 2022-2030

Market Analysis and Insights: Global PD-L1 and PIK3CA Testing Market
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti-PD-1/PD-L1 therapies.

PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.

PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.

The global PD-L1 and PIK3CA Testing market size is projected to reach US$ 1964.3 million by 2028, from US$ 521.8 million in 2021, at a CAGR of 20.6% during 2022-2028.

The classification of PD-L1 and PIK3CA Testing Product includes PD-L1 Testing and PIK3CA Testing. PD-L1 accounted for a share of 80% in the global PD-L1 and PIK3CA Testing Product market.

PD-L1 and PIK3CA Testing Product is widely used in Hospital, Diagnostic Center and Other. In PD-L1 and PIK3CA Testing Product market, the Diagnostic Center holds an important share in terms of Application.

North America is the largest consumption place, with a market share nearly 57% . Following North America, Europe is the second largest consumption place with the market share of 28%.

Market competition is intense. Agilent Technologies, Roche, QIAGEN, Amoy Diagnostics, ACCB Biotech, etc. The top five vendors held 84% of the market share.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global PD-L1 and PIK3CA Testing market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global PD-L1 and PIK3CA Testing market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global PD-L1 and PIK3CA Testing market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global PD-L1 and PIK3CA Testing market.

Impact of Covid-19 Outbreak

This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.

Segmental Analysis

The report has been segmented into product and application segments. The researchers have documented all the products present today in the PD-L1 and PIK3CA Testing market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.

PD-L1 and PIK3CA Testing Breakdown Data by Type

PD-L1 Testing

PIK3CA Testing

PD-L1 and PIK3CA Testing Breakdown Data by Application

Hospital

Diagnostic Center

Others

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Competitive Landscape

This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:

Agilent Technologies

Roche

QIAGEN

EntroGen

Amoy Diagnostics

ACCB Biotech

1 Report Business Overview
1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global PD-L1 and PIK3CA Testing Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.2.2 PD-L1 Testing

1.2.3 PIK3CA Testing

1.3 Market by Application

1.3.1 Global PD-L1 and PIK3CA Testing Market Size Growth Rate by Application, 2017 VS 2021 VS 2028

1.3.2 Hospital

1.3.3 Diagnostic Center

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

2.1 Global PD-L1 and PIK3CA Testing Market Perspective (2017-2028)

2.2 PD-L1 and PIK3CA Testing Growth Trends by Region

2.2.1 PD-L1 and PIK3CA Testing Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 PD-L1 and PIK3CA Testing Historic Market Size by Region (2017-2022)

2.2.3 PD-L1 and PIK3CA Testing Forecasted Market Size by Region (2023-2028)

2.3 PD-L1 and PIK3CA Testing Market Dynamics

2.3.1 PD-L1 and PIK3CA Testing Industry Trends

2.3.2 PD-L1 and PIK3CA Testing Market Drivers

2.3.3 PD-L1 and PIK3CA Testing Market Challenges

2.3.4 PD-L1 and PIK3CA Testing Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top PD-L1 and PIK3CA Testing Players by Revenue

3.1.1 Global Top PD-L1 and PIK3CA Testing Players by Revenue (2017-2022)

3.1.2 Global PD-L1 and PIK3CA Testing Revenue Market Share by Players (2017-2022)

3.2 Global PD-L1 and PIK3CA Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by PD-L1 and PIK3CA Testing Revenue

3.4 Global PD-L1 and PIK3CA Testing Market Concentration Ratio

3.4.1 Global PD-L1 and PIK3CA Testing Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by PD-L1 and PIK3CA Testing Revenue in 2021

3.5 PD-L1 and PIK3CA Testing Key Players Head office and Area Served

3.6 Key Players PD-L1 and PIK3CA Testing Product Solution and Service

3.7 Date of Enter into PD-L1 and PIK3CA Testing Market

3.8 Mergers & Acquisitions, Expansion Plans

4 PD-L1 and PIK3CA Testing Breakdown Data by Type

4.1 Global PD-L1 and PIK3CA Testing Historic Market Size by Type (2017-2022)

4.2 Global PD-L1 and PIK3CA Testing Forecasted Market Size by Type (2023-2028)

5 PD-L1 and PIK3CA Testing Breakdown Data by Application

5.1 Global PD-L1 and PIK3CA Testing Historic Market Size by Application (2017-2022)

5.2 Global PD-L1 and PIK3CA Testing Forecasted Market Size by Application (2023-2028)

6 North America

6.1 North America PD-L1 and PIK3CA Testing Market Size (2017-2028)

6.2 North America PD-L1 and PIK3CA Testing Market Size by Type

6.2.1 North America PD-L1 and PIK3CA Testing Market Size by Type (2017-2022)

6.2.2 North America PD-L1 and PIK3CA Testing Market Size by Type (2023-2028)

6.2.3 North America PD-L1 and PIK3CA Testing Market Share by Type (2017-2028)

6.3 North America PD-L1 and PIK3CA Testing Market Size by Application

6.3.1 North America PD-L1 and PIK3CA Testing Market Size by Application (2017-2022)

6.3.2 North America PD-L1 and PIK3CA Testing Market Size by Application (2023-2028)

6.3.3 North America PD-L1 and PIK3CA Testing Market Share by Application (2017-2028)

6.4 North America PD-L1 and PIK3CA Testing Market Size by Country

6.4.1 North America PD-L1 and PIK3CA Testing Market Size by Country (2017-2022)

6.4.2 North America PD-L1 and PIK3CA Testing Market Size by Country (2023-2028)

6.4.3 United States

6.4.4 Canada

7 Europe

7.1 Europe PD-L1 and PIK3CA Testing Market Size (2017-2028)

7.2 Europe PD-L1 and PIK3CA Testing Market Size by Type

7.2.1 Europe PD-L1 and PIK3CA Testing Market Size by Type (2017-2022)

7.2.2 Europe PD-L1 and PIK3CA Testing Market Size by Type (2023-2028)

7.2.3 Europe PD-L1 and PIK3CA Testing Market Share by Type (2017-2028)

7.3 Europe PD-L1 and PIK3CA Testing Market Size by Application

7.3.1 Europe PD-L1 and PIK3CA Testing Market Size by Application (2017-2022)

7.3.2 Europe PD-L1 and PIK3CA Testing Market Size by Application (2023-2028)

7.3.3 Europe PD-L1 and PIK3CA Testing Market Share by Application (2017-2028)

7.4 Europe PD-L1 and PIK3CA Testing Market Size by Country

7.4.1 Europe PD-L1 and PIK3CA Testing Market Size by Country (2017-2022)

7.4.2 Europe PD-L1 and PIK3CA Testing Market Size by Country (2023-2028)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific PD-L1 and PIK3CA Testing Market Size (2017-2028)

8.2 Asia-Pacific PD-L1 and PIK3CA Testing Market Size by Type

8.2.1 Asia-Pacific PD-L1 and PIK3CA Testing Market Size by Type (2017-2022)

8.2.2 Asia-Pacific PD-L1 and PIK3CA Testing Market Size by Type (2023-2028)

8.2.3 Asia-Pacific PD-L1 and PIK3CA Testing Market Share by Type (2017-2028)

8.3 Asia-Pacific PD-L1 and PIK3CA Testing Market Size by Application

8.3.1 Asia-Pacific PD-L1 and PIK3CA Testing Market Size by Application (2017-2022)

8.3.2 Asia-Pacific PD-L1 and PIK3CA Testing Market Size by Application (2023-2028)

8.3.3 Asia-Pacific PD-L1 and PIK3CA Testing Market Share by Application (2017-2028)

8.4 Asia-Pacific PD-L1 and PIK3CA Testing Market Size by Region

8.4.1 Asia-Pacific PD-L1 and PIK3CA Testing Market Size by Region (2017-2022)

8.4.2 Asia-Pacific PD-L1 and PIK3CA Testing Market Size by Region (2023-2028)

8.4.3 China

8.4.4 Japan

8.4.5 South Korea

8.4.6 Southeast Asia

8.4.7 India

8.4.8 Australia

9 Latin America

9.1 Latin America PD-L1 and PIK3CA Testing Market Size (2017-2028)

9.2 Latin America PD-L1 and PIK3CA Testing Market Size by Type

9.2.1 Latin America PD-L1 and PIK3CA Testing Market Size by Type (2017-2022)

9.2.2 Latin America PD-L1 and PIK3CA Testing Market Size by Type (2023-2028)

9.2.3 Latin America PD-L1 and PIK3CA Testing Market Share by Type (2017-2028)

9.3 Latin America PD-L1 and PIK3CA Testing Market Size by Application

9.3.1 Latin America PD-L1 and PIK3CA Testing Market Size by Application (2017-2022)

9.3.2 Latin America PD-L1 and PIK3CA Testing Market Size by Application (2023-2028)

9.3.3 Latin America PD-L1 and PIK3CA Testing Market Share by Application (2017-2028)

9.4 Latin America PD-L1 and PIK3CA Testing Market Size by Country

9.4.1 Latin America PD-L1 and PIK3CA Testing Market Size by Country (2017-2022)

9.4.2 Latin America PD-L1 and PIK3CA Testing Market Size by Country (2023-2028)

9.4.3 Mexico

9.4.4 Brazil

10 Middle East & Africa

10.1 Middle East & Africa PD-L1 and PIK3CA Testing Market Size (2017-2028)

10.2 Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Type

10.2.1 Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Type (2017-2022)

10.2.2 Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Type (2023-2028)

10.2.3 Middle East & Africa PD-L1 and PIK3CA Testing Market Share by Type (2017-2028)

10.3 Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Application

10.3.1 Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Application (2017-2022)

10.3.2 Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Application (2023-2028)

10.3.3 Middle East & Africa PD-L1 and PIK3CA Testing Market Share by Application (2017-2028)

10.4 Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Country

10.4.1 Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Country (2017-2022)

10.4.2 Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Country (2023-2028)

10.4.3 Turkey

10.4.4 Saudi Arabia

10.4.5 UAE

11 Key Players Profiles

11.1 Agilent Technologies

11.1.1 Agilent Technologies Company Details

11.1.2 Agilent Technologies Business Overview

11.1.3 Agilent Technologies PD-L1 and PIK3CA Testing Introduction

11.1.4 Agilent Technologies Revenue in PD-L1 and PIK3CA Testing Business (2017-2022)

11.1.5 Agilent Technologies Recent Developments

11.2 Roche

11.2.1 Roche Company Details

11.2.2 Roche Business Overview

11.2.3 Roche PD-L1 and PIK3CA Testing Introduction

11.2.4 Roche Revenue in PD-L1 and PIK3CA Testing Business (2017-2022)

11.2.5 Roche Recent Developments

11.3 QIAGEN

11.3.1 QIAGEN Company Details

11.3.2 QIAGEN Business Overview

11.3.3 QIAGEN PD-L1 and PIK3CA Testing Introduction

11.3.4 QIAGEN Revenue in PD-L1 and PIK3CA Testing Business (2017-2022)

11.3.5 QIAGEN Recent Developments

11.4 EntroGen

11.4.1 EntroGen Company Details

11.4.2 EntroGen Business Overview

11.4.3 EntroGen PD-L1 and PIK3CA Testing Introduction

11.4.4 EntroGen Revenue in PD-L1 and PIK3CA Testing Business (2017-2022)

11.4.5 EntroGen Recent Developments

11.5 Amoy Diagnostics

11.5.1 Amoy Diagnostics Company Details

11.5.2 Amoy Diagnostics Business Overview

11.5.3 Amoy Diagnostics PD-L1 and PIK3CA Testing Introduction

11.5.4 Amoy Diagnostics Revenue in PD-L1 and PIK3CA Testing Business (2017-2022)

11.5.5 Amoy Diagnostics Recent Developments

11.6 ACCB Biotech

11.6.1 ACCB Biotech Company Details

11.6.2 ACCB Biotech Business Overview

11.6.3 ACCB Biotech PD-L1 and PIK3CA Testing Introduction

11.6.4 ACCB Biotech Revenue in PD-L1 and PIK3CA Testing Business (2017-2022)

11.6.5 ACCB Biotech Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Author Details

13.3 Disclaimer